



Genekor Medical S.A.
 52, Spaton Ave., 15344, Gerakas, Athens,
 Greece, G.E.MI. nr: 0007856001000
 info@genekor.com www.genekor.com
 Tel. (+30) 210 6032138 Fax. (+30) 210 6032148
 Scientific Director: George Nasioulas PhD

SAMPLE INFORMATION

Name: **Date Sp. Extracted:**
Medical ID: **Req. Physician:**
Date Of Birth: **Report No:**
Material #1: PARAFFIN EMBEDDED TISSUE **Date Received:**
Material #2: **Date Of Report:**
Sample #1 ID: **Tumor type:** METASTATIC LUNG CANCER

Com.Pl.i.t. Dx (27 genes, 7 fusions) | Comprehensive Panel for Individualized Treatment

Report Summary

27 Unique Genes (7 Fusions) analyzed	3 Genomic alterations identified in tumor
7 Biomarker related approved therapies for indication	0 Biomarker related therapies with potential benefit
4 Biomarker related therapies with potential resistance	26 Biomarker related Clinical Trials

Results and Interpretation*

Biomarker	Result	Approved therapies for indication	Therapies with potential benefit	Therapies with potential resistance/toxicity	Clinical Trials
EGFR	Exon 19 c.2235_2249del (p.E746_A750del)	Erlotinib (1A.1) Afatinib (1A.1) Osimertinib (1A.1) Dacomitinib (1A.1) Gefitinib (1A.1) Erlotinib+Ramucirumab (1A.1)	-	-	yes
EGFR	Exon 20 c.2369C>T (p.T790M)	Osimertinib (1A.1)	-	Afatinib (1B) Erlotinib (1A.1) Gefitinib (1A.1)	yes
EGFR	Exon 20 c.2389T>A (p.C797S)	-	-	Osimertinib (1B)	yes
PD-L1 expression (Table S2)	Negative TPS<1%	-	-	-	-

*Note: Variants' Level of Evidence (LoE) (e.g. 1A.1, 2C.1, 1B etc) are based on the Joint consensus recommendation of AMP, ACMG, ASCO and CAP for reporting genetic variants in cancer. For a detailed description of the recommendation please refer to Fig. 1



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255



Name:

Report No:

Genomic Alterations Identified

EGFR: c.2235_2249del (p.E746_A750del)

VAF*:30%

OncoKB

CIViC

PMKB

Treatment information

Patients with in-frame deletions in exon 19 of EGFR are sensitive to EGFR targeted therapies ([PMID: 29075127](#)). They lead to increased receptor dimerisation and increased kinase activity, when compared with the wild-type EGFR protein ([PMID: 31562956](#)). Thus, NSCLC patients carrying this type of mutations have shown responses to treatment with EGFR tyrosine kinase inhibitors (TKIs). Therefore the following treatment options have been approved for such patients:

- The TKI Erlotinib is approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ([PMID: 28017789](#), [PMID: 22285168](#)).
- The TKI Afatinib is approved for patients harboring EGFR mutations. The primary trial supporting approval was Study 1200.32 (LUX-3), a randomized, open-label, multicenter, multinational trial comparing the efficacy of afatinib to cisplatin/pemetrexed chemotherapy doublet for the first-line treatment of metastatic or unresectable, EGFR mutation-positive adenocarcinoma of the lung ([PMID: 32559335](#), [PMID: 28017789](#)). The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I.
- The third-generation EGFR TKI Osimertinib is approved for NSCLC patients with EGFR exon 19 deletions exon 21 L858R mutations as adjuvant therapy after tumor resection and first-line treatment of adult patients with metastatic NSCLC ([PMID: 34301748](#), [PMID: 32955177](#)).
- The oral EGFR kinase inhibitor Dacomitinib is approved for the first-line treatment of patients with metastatic NSCLC and EGFR exon 19 deletion or exon 21 L858R substitution mutations, based on results from the ARCHER 1050 phase 3 clinical study, indicating the drug's potential as a significant treatment advance for this patient population ([PMID: 28958502](#), [PMID: 28958502](#)).
- The kinase inhibitor Gefitinib is approved for the frontline treatment of patients with metastatic, EGFR-positive NSCLC with an exon 19 deletion or exon 21 (L858R) substitution. The FDA approval of Gefitinib is based on data from the Phase IV IFUM1 (IRESSA Follow-Up Measure) study, assessing Gefitinib as a first-line treatment for Caucasian patients with locally advanced or metastatic EGFR mutation-positive NSCLC. This was supported by results from the IPASS2 (IRESSA Pan-ASia Study) clinical trial ([PMID: 24263064](#), [PMID: 21670455](#)).
- Finally, FDA approved ramucirumab in combination with erlotinib for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations. Efficacy was evaluated in RELAY (NCT02411448), a multinational, randomized, double-blind, placebo-controlled, multicenter study, where ramucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib ([PMID: 31591063](#), [33905962](#)).



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

Gene information

EGFR is a member of the ErbB family of structurally related RTKs, consisting of the EGFR (ErbB1), as well as human epidermal growth factor receptor 2 (ErbB2; HER2), ErbB3 (HER3) and ErbB4 (HER4) ([PMID: 11252954, 24269963](#)). These proteins form an array of homo- or heterodimers at the cell surface and play a key role in the normal physiological regulation of cellular proliferation. Aberrant ErbB family signaling is implicated in the development and progression of many human cancers, including non-small cell lung cancer (NSCLC) ([PMID: 15864276](#)). Approximately 15% of NSCLC Caucasians patients and 35% of Asians patient populations harbor tumor associated EGFR mutations ([PMID: 15118073, 15118125, 15329413](#)) in exons 18-21, which code for a portion of the EGFR tyrosine kinase domain. There are approximately five types of mutations, including a point mutation in exon18, deletions in exon 19, insertions in exon 20, a point mutation in exon 20, and a point mutation (L858R) in exon 21.

Variant information

The alteration detected in this patient occurs within exon 19 of the EGFR gene, and results from a 15-bp nucleotide deletion that leads to an in-frame deletion of 5 amino acids. EGFR E746_A750del is the second-most common EGFR mutation and occurs most commonly in lung adenocarcinoma (COSMIC). Patients with in-frame deletions in Exon 19 of EGFR are sensitive to EGFR targeted therapies ([PMID: 29075127](#)).

EGFR: c.2369C>T (p.T790M)

VAF*:25%

OncoKB

CIVIC

PMKB

Treatment information

T790M is the most common secondary EGFR mutation that causes resistance to EGFR tyrosine kinase inhibitors (TKIs). Multiple reports have documented that T790M mediates resistance to gefitinib, erlotinib, afatinib, or cetuximab ([PMID: 18227510; 27811988; 29141884](#)). Osimertinib, is an FDA approved, third-generation EGFR TKI which is associated with clinical benefit in patients harbouring EGFR T790M mutation. It was developed to specifically bind to and induce degradation of EGFR proteins harboring the T790M variant ([PMID: 29141884](#)). In vitro high-throughput study demonstrated that T790M is sensitive to afatinib and osimertinib when co-occurring with EGFR G719A ([PMID: 29141884](#)). Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), under clinical development, for the treatment of non-small cell lung cancer (NSCLC). It is a brain-penetrant, irreversible EGFR-TKI that targets the T790M mutation and activating EGFR mutations Ex19del and L858R, while sparing wild type-EGFR. Lazertinib in combination with amivantamab demonstrated promising clinical activity in the open-label, phase 1 dose-escalation (part 1) and dose-expansion (part 2) CHRYSALIS study (NCT02609776) that is evaluating the efficacy and safety of amivantamab with and without lazertinib in patients with advanced NSCLC harbouring EGFR Exon 19del or L858R activating mutations. Antitumour activity of lazertinib plus amivantamab combination therapy was seen in the ongoing part 2 expansion cohort involving patients with measurable disease who were osimertinib-resistant, chemotherapy-naive or treatment naive. At a median follow-up of 4 months, the ORR in the osimertinib-resistant cohort was 36% and the clinical benefit rate was 60% (<https://doi.org/10.1016/j.annonc.2020.08.1572>). Finally, in a randomized, double-blind, multinational phase III study for the efficacy and safety of lazertinib versus gefitinib assessment as a first-line treatment of patients with EGFRm advanced NSCLC



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

GeneKor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

(LASER301; NCT04248829), Lazertinib demonstrated significant improvement in efficacy compared to gefitinib in the front-line treatment of EGFRm advanced NSCLC, with a comparable safety profile (ESMO Asia Congress, S1560-S1597, 2022).

Variant information

This alteration has been reported as activating. T790M occurs in the ATP binding site (amino acids 790-791, UniProt) of the EGFR kinase domain (amino acids 712-979, UniProt) that is essential for EGFR function. Missense mutations in the kinase domain of EGFR are spread along the kinase coding regions (Exons 18-21) and most of these mutations stimulate kinase activity. A genomic alteration resulting in this amino acid change is recorded within dbSNP (rs121434569) (Jan, 2021). The clinical significance of this alteration in ClinVar is drug response (Jan, 2021).

EGFR: c.2389T>A (p.C797S)

VAF*:24%

OncoKB

CIViC

PMKB

Treatment information

The EGFR C797S is a known resistance mutation. It has been reported in EGFR-mutant lung cancer patients who have developed acquired resistance to Osimertinib ([PMID: 25939061, 26181354](#)). Cells expressing C797S alone or with exon19del were still sensitive to the gefitinib, erlotinib and cetuximab compared with the wildtype ([PMID: 28287083, 29922072, 29141884, 25964297](#)). C797S increases hydrophilicity around residue 797 which made it less preferable for drug binding compared with T790M alone ([PMID: 28456628](#)) and preclinical studies showed that cells with EGFR exon19del-T790M-C797S triple mutations are resistant to T790M-specific third-generation inhibitor osimertinib, compared to EGFR exon19del-T790M double mutation in addition to resistance to gefitinib, erlotinib and afatinib ([PMID: 28287083, 25964297](#)). Among possible osimertinib-resistant mutations, EGFR-C797S was identified as the most common, which accounts for more than 15% but less than 30% of all resistant cases (PMID:31467113).

Variant information

The EGFR exon 20 C797S mutation is located in the EGFR tyrosine kinase domain. While this variant has not been functionally characterized per se, it has been reported that C797S mutation confers resistance to osimertinib ([PMID: 25939061, 26181354](#)). The clinical significance of this alteration in ClinVar is not provided (Apr, 2021).

*VAF: Variant Allele Frequency



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

Associated Treatments Information

Erlotinib

[DrugBank](#)

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Erlotinib is indicated for: - The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. - In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy

Afatinib

[DrugBank](#)

Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

Afatinib is a kinase inhibitor indicated as monotherapy for the first-line treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test, and (b) adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. Recently, as of January 2018, the US FDA approved a supplemental New Drug Application for afatinib for the first line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I.

Osimertinib

[DrugBank](#)

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.

Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.

Dacomitinib

[DrugBank](#)

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed.

Dacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test. Lung cancer is the leading cause of cancer death and NSCLC accounts for 85% of lung cancer cases. From the cases of NSCLC, approximately 75% of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5%. The presence of a mutation in EGFR accounts for more than the 60% of the NSCLC cases and the overexpression of EGFR is associated with frequent lymph node metastasis and poor chemosensitivity.

Gefitinib

[DrugBank](#)

Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib, gefitinib selectively targets the mutant proteins in malignant cells.

Gefitinib is indicated for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

GeneXpert a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

Ramucirumab[DrugBank](#)

Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab blocks ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation and migration of human endothelial cells. Ramucirumab inhibits angiogenesis in animal models. On May 29, 2020, the Food and Drug Administration approved ramucirumab in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.



Electronically Signed by

- **Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188**- **George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255**

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

Clinical Trials to consider

EGFR associated clinical trials

NCT03833154		Phase 3
Title	Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation	
Treatment	Durvalumab Placebo Osimertinib (single-arm, open-label)	
Location	United States, Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Turkey, United Kingdom	

NCT05261399		Phase 3
Title	Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment	
Treatment	Savolitinib Osimertinib Pemetrexed Cisplatin Carboplatin	
Location	United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Poland, Russian Federation, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, Vietnam	

NCT03645928		Phase 2
Title	Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors	
Treatment	Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab	
Location	United States, Canada, France, Germany, Greece, Spain, Switzerland, United Kingdom	

NCT05785208		Phase 4
Title	Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.	
Treatment	Osimertinib	
Location	Italy	

NCT05219162		Phase 4
Title	Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).	
Treatment	Gene Profile explore	
Location	China	



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

NCT03992885		Phase 3
Title	Clinical Study of Combination Therapy With Ectiecicib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.	
Treatment	Icotinib	
Location	China	

NCT04923906		Phase 3
Title	Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations	
Treatment	Aumolertinib Placebo Aumolertinib	
Location	China	

NCT05445791		Phase 3
Title	Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations	
Treatment	Metformin Hydrochloride Placebo	
Location	Mexico	

NCT03924050		Phase 3
Title	Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI	
Treatment	TORIPALIMAB INJECTION(JS001)	
Location	China	

NCT05800223		Phase 3
Title	Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer	
Treatment	Almonertinib SBRT	
Location	China	

NCT04951635		Phase 3
Title	A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer	
Treatment	Almonertinib Placebo Almonertinib	



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

Location	China
-----------------	-------

NCT05388669	Phase 3
Title	A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Treatment	Lazertinib Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) Amivantamab Intravenous
Location	United States, Argentina, Australia, Brazil, Canada, China, France, Germany, Israel, Italy, Japan, Korea, Republic of, Malaysia, Poland, Portugal, Spain, Taiwan, Thailand, Turkey, United Kingdom

NCT01951469	Phase 3
Title	Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer
Treatment	Gefitinib and Pemetrexed/platinum Gefitinib mono-therapy
Location	China

NCT05338970	Phase 3
Title	HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Treatment	Patritumab Deruxtecan Platinum-based chemotherapy
Location	United States, Australia, Austria, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan, United Kingdom

NCT03802240	Phase 3
Title	Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Treatment	Sintilimab IBI305 Pemetrexed Cisplatin Placebo1 Placebo2
Location	China

NCT05104281	Phase 3
Title	Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Treatment	osimertinib oral and bevacizumab intravenously
Location	China

NCT02824458	Phase 3
--------------------	----------------



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

GeneXpert a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

Title	A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Treatment	Apatinib Gefitinib Placebo
Location	China

NCT04988295		Phase 3
Title	A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure	
Treatment	Lazertinib Amivantamab Pemetrexed Carboplatin	
Location	United States, Argentina, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Russian Federation, Spain, Sweden, Taiwan, Turkey, United Kingdom	

NCT05261399		Phase 3
Title	Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment	
Treatment	Savolitinib Osimertinib Pemetrexed Cisplatin Carboplatin	
Location	United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Poland, Russian Federation, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, Vietnam	

NCT05493501		Phase 3
Title	Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer	
Treatment	Aumolertinib monotherapy Osimertinib monotherapy Pemetrexed Cisplatin Carboplatin Paclitaxel Nab paclitaxel Gemcitabine	
Location	United States	

NCT05382728		Phase 3
Title	Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)	
Treatment	TY-9591 placebo Osimertinib Osimertinib placebo TY-9591	
Location	China	

NCT05120349		Phase 3
Title	A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection	



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

Treatment	Osimertinib Placebo
Location	United States, Argentina, Brazil, Canada, China, Germany, Italy, Japan, Korea, Republic of, Malaysia, Poland, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Turkey, United Kingdom, Vietnam

NCT04351555		Phase 3
Title	A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer	
Treatment	Osimertinib Cisplatin Carboplatin Placebo Pemetrexed	
Location	United States, Austria, Brazil, Bulgaria, Canada, Chile, China, France, Germany, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, Vietnam	

NCT04181060		Phase 3
Title	Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer	
Treatment	Bevacizumab Biospecimen Collection Computed Tomography Echocardiography Magnetic Resonance Imaging Multigated Acquisition Scan Osimertinib	
Location	United States	

NCT04143607		Phase 3
Title	ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC	
Treatment	ASK120067 Placebo Gefitinib 250 mg Gefitinib Placebo ASK120067	
Location	China	

NCT05236946		Phase 3
Title	Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT	
Treatment	Stereotactic radiosurgery/whole brain radiotherapy Tyrosine kinase inhibitor	
Location	India	

Press [here](#) for a live search of clinical trials for EGFR



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

Methodology

NGS analysis

DNA was extracted from the sample under investigation using the Qiasymphony DSP DNA Mini Kit (Qiagen). RNA was extracted using the RNeasy FFPE Kit (Qiagen).

Mutation hotspot regions of 27 genes were amplified using an Ion AmpliSeq Panel (Thermo Fisher Scientific). Copy number variations, SNPs, and indels were analysed. Additionally, ALK, ROS1, RET, NTKR1, NTKR2 & NTKR3 fusions and expression and MET exon 14 skipping were tested using an Ion AmpliSeq RNA Fusion Panel (Thermo Fisher Scientific). All fusions detected are confirmed with an alternative method (Real-Time PCR).

Sequencing was carried out using the Next Generation Sequencing platform Ion GeneStudio S5 Prime System (Thermo Fisher Scientific). The detection limit of the method is 2-5% of mutant allelic content, depending on the genomic region. Mutant alleles detected in less than 5% are confirmed.

Ion Torrent OncoPrint Knowledgebase Reporter was used in sequence analysis and interpretation. The application was internally designed and developed by Thermo Fisher Scientific. Variants are reported according to HGVS nomenclature and were classified following ACMG guidelines. Information on therapeutic agents and clinical trials were obtained from publicly available information. Variants, therapies, and trials listed in this report are not ranked in order of potential clinical significance or predicted efficacy for this patient.

**The following hot spot regions are covered by the assay: AKT1 (NM_001014432) exon 4, ALK (NM_001014432) exons 22, 23,25, BRAF (NM_004333) exons 11, 15, CDKN2A (NM_058197) exons 1, 2, CTNNB1 (NM_001904) exon 3, DDR2 (NM_001014796) exons 6, 13, 14, 15, 16, 18, EGFR (NM_005228) exons 12, 18, 19, 20, 21, ERBB2 (NM_004448) exons 19, 20, 21, FBXW7 (NM_033632) exons 5, 8, 9, 10, 11, FGFR1 (NM_023110) exons 4, 7, FGFR2 (NM_022970) exons 9, 12, FGFR3 (NM_001163213) exons 7, 9, 14, 16, 18, HRAS (NM_001130442) exons 2, 3, KEAP1 (NM_203500) exons 2-6, KRAS (NM_033360) exons 2, 3, 4, MAP2K1 (NM_002755) exon 2, MET (NM_001127500) exons 2, 11, 14, 16, 19, NOTCH1 (NM_017617) exons 26, 27, NRAS (NM_002524) exons 2, 3, 4, PIK3CA (NM_006218) exon 10 (p.E542K, p.E545K, p.E545Q, p.E545G, p.E545V, p.Q546K), 14, 21, POLE (NM_006231) exons 9-14, PTEN (NM_000314) exons 1, 3, 6, 7, 8, RET (NM_020975) exons 10-18, SMAD4 (NM_005359) exons 3, 5, 6-12, SMARCA4 (NM_001128849) exons 2-36, STK11 (NM_000455) exons 1-9, TP53 (NM_000546) exons 2-11.

PD-L1 expression by IHC

PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. This assay is indicated as an aid in identifying NSCLC patients for treatment with immunotherapeutic agents.

VENTANA SP263 by IHC (CE IVD) is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone SP263, intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) tissue, using VENTANA BenchMark Series automated staining instrument. The specimen submitted for testing should contain at least 100 viable tumor cells to be considered adequate for evaluation. For cut-off values please refer to table S2.



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

GeneKor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

FISH ALK

FISH analysis was carried out for the detection of rearrangements involving the ALK gene, using the ZytoLight FISH Tissue Implementation Kit (ZytoLight). Microtome sections (3µm) of the sample were hybridized with the ZytoLight SPEC ALK Dual Color Break Apart Probe using Thermobrite (Abbott Molecular) and evaluated microscopically. Signals from 50 nuclei from at least 5 different areas of the sections were microscopically analyzed. Imaging analyses was carried out using the ISIS FISH Imaging System, Metasystems.

Genes Analyzed

27 gene alterations

AKT1	ALK	BRAF	CDKN2A	CTNNB1	DDR2	EGFR	ERBB2	FBXW7	FGFR1
FGFR2	FGFR3	HRAS	KEAP	KRAS	MAP2K1	MET *	NOTCH1	NRAS	PIK3CA
POLE	PTEN	RET	SMAD4	SMARCA4	STK11	TP53			

* MET amplification and MET exon 14 skipping are also included in the analysis

7 fusion transcripts

ALK	ROS1	RET	NTRK1	NTRK2	NTRK3	MET
-----	------	-----	-------	-------	-------	-----



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255



Name:

Report No:

Appendix




Figure 1. Joint consensus recommendation of AMP, ACMG, ASCO and CAP for reporting genetic variants in cancer. [1-2]

1. Leichsenring J, Horak P, Kreutzfeldt S, et al. Int J Cancer. 2019 Dec 1;145(11):2996-3010.
2. Li MM, Datto M, Duncavage EJ, et al. J Mol Diagn. 2017 Jan;19(1):4-23.



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255



Name:

Report No:

Table S2. PD-L1 interpretation and cut-offs.

Cancer type	Therapy	PD-L1	Cut-off	We report
Non-Small Cell Lung Cancer (NSCLC)	Anti-PD-1 ^[1-4]	VENTANA (SP263)	1L TPS ≥ 50% 2L TPS ≥ 1%	%TPS
	Anti-PD-L1 ^[5-7]	VENTANA (SP263)	2L TPS ≥ 1%	%TPS
		VENTANA (SP263)	1L TPS ≥ 50%	%TPS
		VENTANA (SP142)	1L TC ≥ 50% or IC ≥ 10%	%TC/IC
Anti-PD-1 + Anti-CTLA-4 ^[8]	VENTANA (SP263)	1L TPS ≥ 1%	%TPS	
Urothelial cancer (UC)	Anti-PD-1 ^[9]	Dako 22C3	1L CPS ≥ 10	CPS
	Anti-PD-1 ^[19]	VENTANA (SP263)	1L TC ≥ 1%	TC
	Anti-PD-L1 ^[10]	VENTANA (SP142)	2L IC ≥ 5%	%IC
Triple Negative Breast Cancer (TNBC)	Anti-PD-L1 ^[11]	VENTANA (SP142)	1L IC ≥ 1%	%IC
	Anti-PD-1 ^[12] + chemotherapy	Dako 22C3	1L CPS ≥ 10	CPS
Gastric cancer	Anti-PD-1 ^[13]	Dako 22C3	2L CPS ≥ 1	CPS
Gastric cancer HER-2 NEGATIVE (Advanced or metastatic gastric or gastro-oesophageal junction)	Anti-PD-1 ^[18]	Dako 22C3	1L CPS ≥ 5	CPS
Head and neck squamous cell carcinoma (HNSCC)	Anti-PD-1 ^[14,15]	Dako 22C3	1L CPS ≥ 1 2L TPS ≥ 50%	CPS and %TPS
Cervical cancer	Anti-PD-1 ^[16]	Dako 22C3	2L CPS ≥ 1	CPS
Esophageal Adenocarcinoma (HER-2 negative)	Anti-PD-1 ^[17]	Dako 22C3	2L CPS ≥ 10	CPS
	Anti-PD-1 ^[18]	Dako 22C3	1L CPS ≥ 5	CPS
metastatic oesophageal SQUAMOUS cell carcinoma	Anti-PD-1 ^[17]	Dako 22C3	2L CPS ≥ 10	CPS
	Anti-PD-1 ^[18]	Dako 22C3	1L TC ≥ 1%	TC

1. Reck M, et al N Engl J Med. 2016 Nov 10;375(19):1823-1833 | 2. Herbst RS, et al Lancet. 2016 Apr 9;387(10027):1540-50. | 3. Brahmer J, et al N Engl J Med. 2015 Jul 9;373(2):123-35. | 4. Borghaei H, et al N Engl J Med. 2015 Oct 22;373(17):1627-39. | 5. Antonia SJ, et al N Engl J Med. 2018 Dec 13;379(24):2342-2350. | 6. Sezer A, et al Lancet. 2021 Feb 13;397(10274):592-604. | 7. Herbst RS, et al N Engl J Med. 2020;383(14):1328-1339. | 8. Hellmann MD, et al 2019 N Engl J Med. 2019 Nov 21;381(21):2020-2031. | 9. Balar AV, et al Lancet Oncol. 2017 Nov;18(11):1483-1492. | 10. Balar AV, et al Lancet. 2017 Jan 7;389(10064):67-76. | 11. Schmid P, et al N Engl J Med. 2018 Nov 29;379(22):2108-2121. | 12. Cortes J, et al 2020 J Clin Oncol. 2020;38(suppl 15):1000. | 13. Bang YJ, et al 2019 Mar 25. doi: 10.1007/s10120-018-00909-5. | 14. Cohen EEW, et al Lancet Oncol. 2019 Jan 12;393(10167):156-167. | 15. Rischin D, et al 2019 J Clin Oncol 37, (suppl; abstr 6000) | 16. Chung HC, et al 2018 J Clin Oncol 36:15_suppl, 5522-5522 | 17. Kojima T, et al J Clin Oncol. 2020;38(35):4138-4148. | 18. Yelena Y Janjigian et al, 2021. 10.1016/S0140-6736(21)00797-2 | 19. Bajorin DF et al. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.

TPS: Tumor Proportion Score =
$$\frac{\text{\#PD-L1 positive tumor cells}}{\text{Total \#PD-L1 positive+PD-L1 negative tumor cells}}$$

TC: tumor cell

CPS: Combined Positive Score =
$$\frac{\text{\#PD-L1 staining cells (tumor cells,lymphocytes,macrophages)}}{\text{Total \# of viable tumor cells}}$$

IC: immune cell



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Name:

Report No:

References

1. Tops BB, Normanno N, Kurth H, Amato E, Mafficini A, Rieber N, Le Corre D, Rachiglio AM, Reiman A, Sheils O, Noppen C, Lacroix L, Cree IA, Scarpa A, Ligtenberg MJ, Laurent-Puig P. **Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium.** BMC Cancer. 2015 Jan 31;15:26. doi: 10.1186/s12885-015-1015-5. [\(PMID: 25637035\)](#)
2. Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. [\(PMID: 28958502\)](#)
3. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bannouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. [\(PMID: 23816960\)](#)
4. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. [\(PMID: 20022809\)](#)
5. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazekov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. [\(PMID: 21670455\)](#)
6. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazekov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. [\(PMID: 29151359\)](#)
7. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. doi: 10.1016/S1470-2045(12)70086-4. [\(PMID: 22452895\)](#)
8. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bannouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. [\(PMID: 25589191\)](#)
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

- standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. (PMID: 22285168)
10. Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. *J Clin Oncol.* 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. (PMID: 29864379)
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med.* 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. (PMID: 19692680)
12. CiÃ“nas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, Mudie N, Wu YL. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). *Lung Cancer.* 2016 Dec;102:30-37. doi: 10.1016/j.lungcan.2016.10.007. (PMID: 27987585)
13. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. *J Clin Oncol.* 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. (PMID: 22370314)
14. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med.* 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. (PMID: 20573926)
15. PUBMED:
16. Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. *Ann Oncol.* 2014 Feb;25(2):423-8. doi: 10.1093/annonc/mdt573. (PMID: 24478319)
17. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncol.* 2015 Jul;16(7):830-8. doi: 10.1016/S1470-2045(15)00026-1. (PMID: 26051236)
18. Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Kobayashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. *J Clin Oncol.* 2013 Sep 20;31(27):3335-41. doi: 10.1200/JCO.2012.45.0981. (PMID: 23816963)
19. JÃ“nne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med.* 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817. (PMID: 25923549)
20. Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). *J Clin Oncol.* 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. (PMID: 30059262)
21. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol.* 2016 Dec;17(12):1643-1652. doi: 10.1016/S1470-2045(16)30508-3. (PMID: 27751847)



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)

Name:

Report No:

22. Malapelle U, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G. Osimertinib. Recent Results Cancer Res. 2018;211:257-276. doi: 10.1007/978-3-319-91442-8_18. PMID: 30069773.
23. Bollinger MK, Agnew AS, Mascara GP. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract. 2018 Jul;24(5):379-388. doi: 10.1177/1078155217712401. Epub 2017 May 31. PMID: 28565936.
24. Du X, Yang B, An Q, Assaraf YG, Cao X, Xia J. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation (N Y). 2021 Apr 3;2(2):100103. doi: 10.1016/j.xinn.2021.100103. PMID: 34557754; PMCID: PMC8454558.
25. Tan CS, Cho BC, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8. PMID: 26898616.
26. Matsuo N et al. **Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.** Sci Rep. 2016 Nov 4;6:36458. doi: 10.1038/srep36458. [\(PMID: 27811988\)](#)
27. Hynes NE et al. **ERBB receptors and cancer: the complexity of targeted inhibitors.** Nat Rev Cancer. 2005 May;5(5):341-54. doi: 10.1038/nrc1609. [\(PMID: 15864276\)](#)
28. Kong LL et al. **Structural pharmacological studies on EGFR T790M/C797S.** Biochem Biophys Res Commun. 2017 Jun 24;488(2):266-272. doi: [\(PMID: 28456628\)](#)
29. Wu YL et al. **Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised,** Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. [\(PMID: 28958502\)](#)
30. Yu HA et al. **Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase** JAMA Oncol. 2015 Oct;1(7):982-4. doi: 10.1001/jamaoncol.2015.1066. [\(PMID: 26181354\)](#)
31. Uchibori K et al. **Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.** Nat Commun. 2017 Mar 13;8:14768. doi: 10.1038/ncomms14768. [\(PMID: 28287083\)](#)
32. Roskoski R Jr. **The ErbB/HER family of protein-tyrosine kinases and cancer.** Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. [\(PMID: 24269963\)](#)
33. Ponce Aix S et al. **RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United** Cancer Treat Res Commun. 2021;27:100378. doi: 10.1016/j.ctarc.2021.100378. [\(PMID: 33905962\)](#)
34. Harrison PT et al. **Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.** Semin Cancer Biol. 2020 Apr;61:167-179. doi: 10.1016/j.semcancer.2019.09.015. [\(PMID: 31562956\)](#)
35. Pao W et al. **EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.** Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. doi: [\(PMID: 15329413\)](#)
36. Paez JG et al. **EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.** Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. [\(PMID: 15118125\)](#)
37. Castellanos E et al. **Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.** J Thorac Oncol. 2017 Apr;12(4):612-623. doi: 10.1016/j.jtho.2016.12.014. [\(PMID: 28017789\)](#)
38. Yun CH et al. **The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.** Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5. doi: [\(PMID: 18227510\)](#)
39. Nakagawa K et al. **Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind,** Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. [\(PMID: 31591063\)](#)



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Name:

Report No:

40. Koch AL et al. **FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.** Clin Cancer Res. 2021 Dec 15;27(24):6638-6643. doi: [\(PMID: 34301748\)](#)
41. Thress KS et al. **Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.** Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. [\(PMID: 25939061\)](#)
42. Kobayashi K et al. **Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer.** Onco Targets Ther. 2018 Jun 6;11:3335-3343. doi: 10.2147/OTT.S161745. eCollection [\(PMID: 29922072\)](#)
43. Douillard JY et al. **First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.** Br J Cancer. 2014 Jan 7;110(1):55-62. doi: 10.1038/bjc.2013.721. [\(PMID: 24263064\)](#)
44. Yarden Y et al. **Untangling the ErbB signalling network.** Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37. doi: 10.1038/35052073. [\(PMID: 11252954\)](#)
45. Niederst MJ et al. **The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment** Clin Cancer Res. 2015 Sep 1;21(17):3924-33. doi: 10.1158/1078-0432.CCR-15-0560. [\(PMID: 25964297\)](#)
46. Kohsaka S et al. **A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.** Sci Transl Med. 2017 Nov 15;9(416):eaan6566. doi: 10.1126/scitranslmed.aan6566. [\(PMID: 29141884\)](#)
47. Nakamura A et al. **Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group** Oncologist. 2020 Oct;25(10):e1451-e1456. doi: 10.1634/theoncologist.2020-0545. [\(PMID: 32559335\)](#)
48. Memon AA et al. **EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma.** Onco Targets Ther. 2017 Sep 18;10:4607-4613. doi: 10.2147/OTT.S130051. [\(PMID: 29075127\)](#)
49. Lynch TJ et al. **Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.** N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. [\(PMID: 15118073\)](#)
50. <https://civic.genome.wustl.edu/>
51. <http://cancer.sanger.ac.uk/>
52. <https://www.clinicaltrials.gov>
53. <http://atlasgeneticsoncology.org>
54. <https://www.oncokb.org/>
55. <https://www.mycancergenome.org/>
56. <https://pmkb.org/>



Electronically Signed by

- Stella Maxouri, Ph.D., Molecular Biologist, AMKA:22098802188

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)